Evidence map›Paper›PMID 39500881›Full record

ArticleNature communications2024

Neuroblastoma plasticity during metastatic progression stems from the dynamics of an early sympathetic transcriptomic trajectory.

Benjamin Villalard, Arjan Boltjes, Florie Reynaud, Olivier Imbaud, Karine Thoinet, Ilse Timmerman, Séverine Croze, Emy Theoulle, Gianluigi Atzeni, Joël Lachuer and 4 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Epigenetic crosstalk in neuroblastoma development and progression.Frontiers in cell and developmental biology · 2026
    Review
  5. Regulation ofBiology · 2025
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Benjamin VillalardUniversité Claude Bernard Lyon 1, MeLis, CNRS UMR 5284, INSERM U1314, Faculté de Médecine et de Pharmacie - 8 avenue Rockefeller, F-69008, Lyon, France.ORCID 0000-0002-4187-6389
Arjan Boltjes *Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0002-6338-051X
Florie Reynaud *Université Claude Bernard Lyon 1, MeLis, CNRS UMR 5284, INSERM U1314, Faculté de Médecine et de Pharmacie - 8 avenue Rockefeller, F-69008, Lyon, France.ORCID 0000-0002-1653-7377
Olivier ImbaudUniversité Claude Bernard Lyon 1, MeLis, CNRS UMR 5284, INSERM U1314, Faculté de Médecine et de Pharmacie - 8 avenue Rockefeller, F-69008, Lyon, France.
Karine ThoinetUniversité Claude Bernard Lyon 1, MeLis, CNRS UMR 5284, INSERM U1314, Faculté de Médecine et de Pharmacie - 8 avenue Rockefeller, F-69008, Lyon, France.
Ilse TimmermanPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Séverine CrozeProfileXpert, Claude Bernard Lyon 1 University, SFR santé LYON-EST, UCBL-INSERM US 7-CNRS UMS 3453, 69008, Lyon, France.
Emy TheoulleUniversité Claude Bernard Lyon 1, MeLis, CNRS UMR 5284, INSERM U1314, Faculté de Médecine et de Pharmacie - 8 avenue Rockefeller, F-69008, Lyon, France.
Gianluigi AtzeniCellenion SASU - Bioserra 2 - 60 avenue Rockefeller, F-69008, Lyon, France.
Joël LachuerProfileXpert, Claude Bernard Lyon 1 University, SFR santé LYON-EST, UCBL-INSERM US 7-CNRS UMS 3453, 69008, Lyon, France.
Jan J MolenaarPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Godelieve A M TytgatPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Céline Delloye-BourgeoisUniversité Claude Bernard Lyon 1, MeLis, CNRS UMR 5284, INSERM U1314, Faculté de Médecine et de Pharmacie - 8 avenue Rockefeller, F-69008, Lyon, France. celine.delloye@lyon.unicancer.fr.ORCID 0000-0002-7162-0034
Valérie CastellaniUniversité Claude Bernard Lyon 1, MeLis, CNRS UMR 5284, INSERM U1314, Faculté de Médecine et de Pharmacie - 8 avenue Rockefeller, F-69008, Lyon, France. valerie.castellani@univ-lyon1.fr.ORCID 0000-0001-9623-9312

Funding

Fondation ARC pour la Recherche sur le Cancer (ARC Foundation for Cancer Research) PJA20181207900Institut National Du Cancer (French National Cancer Institute) PLBIO18-161
6 · The paper itself

Abstract

Despite their indisputable importance in neuroblastoma (NB) pathology, knowledge of the bases of NB plasticity and heterogeneity remains incomplete. They may be rooted in developmental trajectories of their lineage of origin, the sympatho-adrenal neural crest. We find that implanting human NB cells in the neural crest of the avian embryo allows recapitulating the metastatic sequence until bone marrow involvement. Using deep single cell RNA sequencing, we characterize transcriptome states of NB cells and their dynamics over time and space, and compare them to those of fetal sympatho-adrenal tissues and patient tumors and bone marrow samples. Here we report remarkable transcriptomic proximities restricted to an early sympathetic neuroblast branch that co-exist with phenotypical adaptations over disease progression and recapitulate intratumor and interpatient heterogeneity. Combining avian and patient datasets, we identify a list of genes upregulated during bone marrow involvement and associated with growth dependency, validating the relevance of our multimodal approach.

Indexed as

Disease ProgressionNeural CrestNeuroblastomaTranscriptomeAnimalsBone MarrowCell Line, TumorChick EmbryoGene Expression ProfilingGene Expression Regulation, NeoplasticHumansNeoplasm MetastasisSingle-Cell AnalysisSympathetic Nervous System

Identifiers

PMID39500881
PMCPMC11538482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.